There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Denali Therapeutics (DNLI – Research Report), Regulus (RGLS – Research Report) and Clene (CLNN – Research Report) with bullish sentiments.
Denali Therapeutics (DNLI)
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Denali Therapeutics, with a price target of $105.00. The company’s shares closed last Tuesday at $31.61.
According to TipRanks.com, Fein is a 2-star analyst with an average return of 0.3% and a 42.8% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and Deciphera Pharmaceuticals.
Denali Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $56.50, an 86.8% upside from current levels. In a report issued on June 6, Oppenheimer also maintained a Buy rating on the stock with a $68.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Regulus (RGLS)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Regulus today and set a price target of $9.00. The company’s shares closed last Tuesday at $1.37.
According to TipRanks.com, Selvaraju has 0 stars on 0-5 stars ranking scale with an average return of -13.7% and a 33.3% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, MoonLake Immunotherapeutics, and Entrada Therapeutics Inc.
Currently, the analyst consensus on Regulus is a Moderate Buy with an average price target of $9.00.
Clene (CLNN)
In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Clene, with a price target of $7.00. The company’s shares closed last Tuesday at $1.00, close to its 52-week low of $0.82.
According to TipRanks.com, Pantginis is a 4-star analyst with an average return of 4.7% and a 43.2% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Genenta Science SpA Sponsored ADR, Bioline RX Ltd Sponsored ADR, and Actinium Pharmaceuticals.
Clene has an analyst consensus of Strong Buy, with a price target consensus of $5.50, implying a 522.9% upside from current levels. In a report issued on June 16, Benchmark Co. also reiterated a Buy rating on the stock with a $7.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on DNLI: